Sponsor: Alimera Sciences
Purpose: To compare the visual improvement of patients given fluocinolone acetonide after previous laser therapy to reduce their macular edema. The study lasts 3 years.

Sponsor: Allergan Pharmaceuticals
Purpose: To evaluate the safety and compare the visual improvement of patients given combined dexamethasone and laser photocoagulation with patients treated with just laser photocoagulation to reduce their macular edema. The study lasts between 12 and 16 months and consists of 11 scheduled visits.

Age-related Macular Degeneration Studies

Sponsor: (OSI) Eyetech, Inc.
Purpose: To compare the visual results of patients with wet age-related macular degeneration who have been treated with 1 or 2 treatments of Avasitin or Lucentis and then treated with Macugen every 6 weeks for 10 months. The study lasts 54 weeks.

Sponsor: Acuity Pharmaceuticals, Inc.
Purpose: To evaluate the effectiveness of bevasiranib sodium given as maintenance every 8 weeks following 3 doses of Lucentis in patients with wet age-related macular degeneration. This study lasts 2 years.

Sponsor: Regeneron Pharmaceuticals, Inc.
Purpose: To evaluate the effectiveness of vision loss and the safety of repeated doses of VEGF Trap in patients with wet age-related macular degeneration. The study lasts 3 years.

Sponsor: Glaxo-Smith-Kline
Purpose: To evaluate the safety and efficacy of a newly developed medication in patients with wet age-related macular degeneration. This study is slated to begin enrolling patients in early 2008.

Cataract Surgery Studies

Sponsor: Alcon Laboratories, Inc.
Purpsose: To compare the use of DisCoVisc with Helon5 in cataract surgery patients who have difficult to dilate pupils or Intraoperative Floppy Iris Syndrome (IFIS). The study lasts 6 weeks.

Sponsor: Alcon Laboratories, Inc.
Purpose: To compare the use of Duo Visc, Amvisc Plus, Healon and DisCoVisc in cataract patients with healthy eyes other than their cataract. This study last approximately 6 weeks and consists of 5 scheduled visits.

Glaucoma Studies

Sponsor: Alcon Laboratories, Inc
Purpose: To compare the results of using Xalatan and Azopt to control intraocular pressure in patients who have inadequately controlled intraocular pressure using Xalatan alone. The study lasts 12 weeks and consists of 4 scheduled visits. Patients who consent to do this study will be required to have their eye pressure obtained three (3) times a day on 2 of the 4 scheduled visit days.

If you have further questions, or are interested in taking part in one of these clinical trials, contact Stephen Infantino, Director of Clinical Research at steve@eyecenters.com or (502) 214-3397.